Bellicum Pharmaceuticals Inc. buy klostergang
Summary
This prediction ended on 26.11.19 with a price of €7.80. The BUY prediction by klostergang for Bellicum Pharmaceuticals Inc. performed very badly with a performance of -68.44%. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Bellicum Pharmaceuticals Inc. | - | - | - | - |
iShares Core DAX® | 2.594% | -1.861% | 13.242% | 16.867% |
iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% | 45.898% |
iShares Nikkei 225® | 0.687% | -8.704% | 17.510% | 2.760% |
iShares S&P 500 | 2.209% | -1.988% | 27.632% | 42.955% |
Comments by klostergang for this prediction
In the thread Bellicum Pharmaceuticals Inc. diskutieren
klostergang stimmt dem Sentiment von 'Buy' zu
The June 26, 2017 updated results Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) presented for BPX-501, validated its controllable cell therapy platform. This, according to the firm, is supportive of a potential new standard of care in haploidentical stem cell transplant.
BPX-501 is an allogenic T cell add-back product used after a T-cell depleted haploidentical allogenic hematopoietic stem cell transplant for both benign and malignant hematologic diseases.
As such, Wells Fargo has an Outperform rating on the shares of Bellicum, with a $31 price target.
Stopped prediction by klostergang for Bellicum Pharmaceuticals Inc.
Bellicum Pharmaceuticals Inc.
15.03.20
04.11.21
17.06.21
Bellicum Pharmaceuticals Inc.
13.02.20
25.02.20
25.02.20
Bellicum Pharmaceuticals Inc.
02.07.17
20.05.19
20.05.19